Xia Shijun, Wang Chi, Du Xin, Guo Lizhu, Du Jing, Zheng Yang, Wu Shulin, Guang Xuefeng, Zhou Xianhui, Lin Hongbo, Cheng Xiaoshu, Anderson Craig S, Huffman Mark D, Dong Jianzeng, Yuan Yiqiang, Ma Changsheng
Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Heart Health Research Centre, Beijing, China.
Cerebrovasc Dis. 2022;51(3):384-393. doi: 10.1159/000519309. Epub 2021 Dec 8.
Health care quality and insurance coverage have improved with economic development in China, but the burden of cardiovascular diseases (CVDs) continues to increase with ongoing gaps in prevention. We aimed to compare the uptake of secondary CVD prevention between stroke and coronary heart disease (CHD) patients in China.
In a cross-sectional community-based survey of 47,841 adults (age ≥45 years) in 7 regions of China between 2014 and 2016, we identified those with a history of stroke or CHD to quantify disparities in conventional secondary CVD prevention strategies in multivariable logistic regression models.
There were 4,105 and 1,022 participants with a history of stroke and CHD, respectively. Compared to participants with CHD, those with a history of stroke were significantly less likely to be taking blood-pressure-lowering (39.7% vs. 53%), lipid-lowering (13.7% vs. 36.8%), and antiplatelet (20.8% vs. 50.6%) agents, at least one (48.9% vs. 70.8%) or all 3 recommended medicines (6.1% vs. 24.0%), and were less likely to achieve a lipid-cholesterol target (30.3% vs. 44.0%). Participants with a history of stroke achieved less optimal secondary prevention goals for medication use, either from any (adjusted odds ratio [aOR] 0.54, 95% confidence interval [CI] 0.44-0.66) or all 3 medications (aOR 0.27, 95% CI 0.20-0.36), as well as better blood pressure (aOR 0.81, 95% CI 0.66-0.98) and low-density lipoprotein cholesterol (aOR 0.34, 95% CI 0.27-0.43) levels of control. There were no significant differences in weight, smoking, or physical activity between the groups.
Stroke patients had lower use of secondary CVD-preventive medication and achieved lower levels of risk factor control than those of CHD patients in China. Nationwide disease-specific strategies, and better education of participants and health care providers, may narrow these gaps.
随着中国经济发展,医疗质量和保险覆盖范围有所改善,但心血管疾病(CVD)负担仍在增加,预防方面仍存在差距。我们旨在比较中国中风患者和冠心病(CHD)患者二级心血管疾病预防措施的采用情况。
在2014年至2016年对中国7个地区47841名成年人(年龄≥45岁)进行的基于社区的横断面调查中,我们确定了有中风或冠心病病史的患者,以在多变量逻辑回归模型中量化传统二级心血管疾病预防策略的差异。
分别有4105名和1022名有中风和冠心病病史的参与者。与冠心病患者相比,有中风病史的患者服用降压药(39.7%对53%)、降脂药(13.7%对36.8%)和抗血小板药(20.8%对50.6%)、至少一种(48.9%对70.8%)或所有三种推荐药物(6.1%对24.0%)的可能性显著降低,且达到血脂胆固醇目标的可能性也较低(30.3%对44.0%)。有中风病史的参与者在药物使用的二级预防目标方面,无论是任何一种(调整优势比[aOR]0.54,95%置信区间[CI]0.44 - 0.66)还是所有三种药物(aOR 0.27,95% CI 0.20 - 0.36),以及更好的血压(aOR 0.81,95% CI 0.66 - 0.98)和低密度脂蛋白胆固醇(aOR 0.34,95% CI 0.27 - 0.43)水平控制方面,都未达到最佳状态。两组在体重、吸烟或身体活动方面无显著差异。
在中国,中风患者二级心血管疾病预防药物的使用低于冠心病患者,且危险因素控制水平也较低。全国性的针对特定疾病的策略,以及对参与者和医疗服务提供者更好的教育,可能会缩小这些差距。